Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review

Glasgow, Akisha; Sechrist, Haley; Bomeisl, Phillip; Gilmore, Hannah; Harbhajanka, Aparna

doi:10.1007/s12282-020-01163-3

Cited by 8 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar concordance rates were previously published. 7,16,24,25 Of note, Magee equation 2 did not perform appreciably better than the original Magee equation that had been published 5 years earlier and that excludes tumor size as a variable (Figures 2 through 5). After the results of the TAILORx trial were published, 3,4 most clinicians adopted a RS threshold of more than 25 to determine potential chemotherapy benefit, at least in postmenopausal women.…”

Section: Arch Pathol Lab Medmentioning

confidence: 82%

“…Similar data were reported in previous studies. 7,15,16 Similarly, only 7 of 143 (5%) of tumors with a combined grade of 1 and 10 of 248 or…”

Section: Discussionmentioning

confidence: 99%

“…This observation is remarkably similar to previous reports. 10,13,14,16,24 With regard to concordance across 3 categories (low, intermediate, high), agreement ranged from 64% to 73% for the conventional cutoffs, and from 53% to 58% for the TAILORx cutoffs. This may partly be explained by the fact that the BCPS and Magee equations were developed for optimal concordance of the respective model with the Oncotype RS using the thresholds that were generally used at the time.…”

Section: Arch Pathol Lab Medmentioning

confidence: 99%

“…13 of 306 (4%) of tumors with high PR content (modified Hscore !200 or Allred score 7-8, respectively) had an RS greater than 25, confirming other reports. 7,[16][17][18] It was previously shown that ER-positive tumors can be stratified into luminal A and luminal B subtypes using expression levels of ER, PR, HER2, and Ki-67 (or, alternatively, tumor grade). 19 The immunohistochemical subtypes correlate variably well with the molecularly defined subtypes.…”

Section: Arch Pathol Lab Medmentioning

confidence: 99%

See 3 more Smart Citations

Pathobiologic Stratification of Oncotype DX Recurrence Scores and Comparative Validation of 3 Surrogate Models

Mohamed

Kousar

Wong

et al. 2022

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.— The Oncotype DX Recurrence Score (RS) predicts recurrence and chemotherapy benefit in early-stage estrogen receptor positive breast cancer patients. Cost and unavailability are 2 major disadvantages of the assay. Multiple models have been developed to predict the RS. Objective.— To predict RS based on histopathologic and biomarker features, and to measure concordance and correlation with RS of the following 3 algorithms: breast cancer prognostic score, Magee0, and Magee2. Design.— Breast cancer cases with available RS were reviewed (n = 442). RS categories were stratified by pathologic and biomarker variables. Histopathologic and biomarker data were abstracted from pathology reports, and RS was calculated by each model. Correlation and concordance between models and RS were calculated. Results.— Less than 5% of breast cancers with lobular features, low-grade tumors, carcinomas with high progesterone receptor content, or luminal A tumors had an RS greater than 25. Breast cancer prognostic score, Magee0, and Magee2 demonstrated correlation coefficients with RS of 0.63, 0.61, and 0.62, respectively. Two-step discordances were uncommon. When an RS of 25 was used to separate high-risk from non–high-risk cases, concordance rates of 86% to 88% were achieved. Conclusions.— High RS was observed only in a small percentage of pure or mixed lobular carcinomas, low-grade or luminal A tumors, and tumors with high progesterone receptor expression, suggesting that these cancers may not require Oncotype testing. All 3 surrogate models demonstrated comparable correlation and high concordance with the RS when a cutoff of 25 was used, suggesting their utility in cases where the actual RS is unavailable.

show abstract

Section: Arch Pathol Lab Medmentioning

confidence: 82%

“…Similar data were reported in previous studies. 7,15,16 Similarly, only 7 of 143 (5%) of tumors with a combined grade of 1 and 10 of 248 or…”

Section: Discussionmentioning

confidence: 99%

Section: Arch Pathol Lab Medmentioning

confidence: 99%

Section: Arch Pathol Lab Medmentioning

confidence: 99%

See 2 more Smart Citations

Pathobiologic Stratification of Oncotype DX Recurrence Scores and Comparative Validation of 3 Surrogate Models

Mohamed

Kousar

Wong

et al. 2022

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…The average Magee score was obtained from the online website. 29 For consistency, the same cut-offs used to categorise Oncotype DX RS were applied to the estimated scores derived from the equation. The NPx was calculated for the study cohort for both BCSS and DMFS, as per our previous study.…”

Section: Methodsmentioning

confidence: 99%

Evaluation oncotype DX^® 21‐gene recurrence score and clinicopathological parameters: a single institutional experience

et al. 2023

View full text Add to dashboard Cite

Aims: Oncotype DX recurrence score (RS) is a clinically validated assay, which predicts the likelihood of disease recurrence in oestrogen receptor-positive/ HER2-negative (ER+/HER2À) breast cancer (BC). In this study we aimed to compare the performance of Oncotype DX against the conventional clinicopathological parameters using a large BC cohort diagnosed in a single institution. Methods and results: A cohort (n = 430) of ER+/ HER2À BC patients who were diagnosed at the Nottingham University Hospitals NHS Trust and had Oncotype DX testing was included. Correlation with the clinicopathological and other biomarkers, including the proliferation index, was analysed. The median Oncotype DX RS was 17.5 (range = 0-69). There was a significant association between high RS and grade 3 tumours. No grade 1 BC or grade 2 tumours with mitosis score 1 showed high RS. Low RS was significantly associated with special tumour types where none of the patients with classical lobular or tubular carcinomas had a high RS. There was an inverse association between RS and levels of ER and progesterone receptor (PR) expression and a positive linear correlation with Ki67 labelling index. Notably, six patients who developed recurrence had an intermediate RS; however, four of these six cases (67%) were identified as high-risk disease when the conventional clinical and molecular parameters were considered. Conclusion: Oncotype DX RS is correlated strongly with the conventional clinicopathological parameters in BC. Some tumour features such as tumour grade, type, PR status and Ki67 index can be used as surrogate markers in certain scenarios.

show abstract

Recurrence score-predicted value derived from estrogen receptor, tumor-infiltrating lymphocytes, progesterone receptor, and Ki-67 may substitute for the Oncotype DX recurrence score in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)− breast cancer

Sotome,

Maeda,

Yanagisawa

et al. 2025

Annals of Diagnostic Pathology

View full text Add to dashboard Cite

Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review

Cited by 8 publications

References 28 publications

Pathobiologic Stratification of Oncotype DX Recurrence Scores and Comparative Validation of 3 Surrogate Models

Pathobiologic Stratification of Oncotype DX Recurrence Scores and Comparative Validation of 3 Surrogate Models

Evaluation oncotype DX^® 21‐gene recurrence score and clinicopathological parameters: a single institutional experience

Recurrence score-predicted value derived from estrogen receptor, tumor-infiltrating lymphocytes, progesterone receptor, and Ki-67 may substitute for the Oncotype DX recurrence score in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)− breast cancer

Contact Info

Product

Resources

About

Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review

Cited by 8 publications

References 28 publications

Pathobiologic Stratification of Oncotype DX Recurrence Scores and Comparative Validation of 3 Surrogate Models

Pathobiologic Stratification of Oncotype DX Recurrence Scores and Comparative Validation of 3 Surrogate Models

Evaluation oncotype DX® 21‐gene recurrence score and clinicopathological parameters: a single institutional experience

Recurrence score-predicted value derived from estrogen receptor, tumor-infiltrating lymphocytes, progesterone receptor, and Ki-67 may substitute for the Oncotype DX recurrence score in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)− breast cancer

Contact Info

Product

Resources

About

Evaluation oncotype DX^® 21‐gene recurrence score and clinicopathological parameters: a single institutional experience